ArticleThe annals of applied statistics2024
DYNAMIC RISK PREDICTION FOR CERVICAL PRECANCER SCREENING WITH CONTINUOUS AND BINARY LONGITUDINAL BIOMARKERS.
Article in The annals of applied statistics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Comparison of Testing Procedures for Detecting Short- and Long-Term Effects of Biomarkers for Cancer Screening.Statistics in medicine · 2026Article
- DYNAMIC RISK PREDICTION FOR CERVICAL PRECANCER SCREENING WITH CONTINUOUS AND BINARY LONGITUDINAL BIOMARKERS.The annals of applied statistics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dynamic risk prediction that incorporates longitudinal measurements of biomarkers is useful in identifying high-risk patients for better clinical management. Our work is motivated by the prediction of cervical precancers. Currently, Pap cytology is used to identify HPV-positive (HPV+) women at high-risk of cervical precancer, but cytology lacks accuracy and reproducibility. Molecular markers, like HPV DNA methylation, that are closely linked to the carcinogenic process show promise of improved risk stratification. We are interested in developing a dynamic risk model that uses all longitudinal biomarker information to improve precancer risk estimation. We propose a joint model to link both the continuous methylation biomarker and a binary cytology biomarker to the time to precancer outcome using shared random effects. The model uses a discretization of the time scale to allow for closed-form likelihood expressions, thereby avoiding potential high dimensional integration of the random effects. The method handles an interval-censored time-to-event outcome, due to intermittent clinical visits, incorporates sampling weights to deal with stratified sampling data and can provide immediate and five-year risk estimates that may inform clinical decision-making. Applying the method to longitudinally measured HPV methylation data improves risk stratification for triage of HPV+ women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.